#BEGIN_DRUGCARD DB00251

# AHFS_Codes:
84:04.08.08

# ATC_Codes:
G01AG02

# Absorption:
Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations

# Biotransformation:
Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.

# Brand_Mixtures:
Not Available

# Brand_Names:
Fungistat
Gyno-Terazol
Terazol
Terazol 3
Terazol 7
Tercospor

# CAS_Registry_Number:
67915-31-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C26H31Cl2N5O3

# Chemical_IUPAC_Name:
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2247651

# Description:
Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections. [Wikipedia]

# Dosage_Forms:
Bead	Intravaginal
Cream	Intravaginal

# Drug_Category:
Antifungal Agents
Antifungals

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.5

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Terconazole

# HET_ID:
Not Available

# Half_Life:
6.9 hours (range 4.0-11.3)

# InChI_Identifier:
InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1

# InChI_Key:
InChIKey=BLSQLHNBWJLIBQ-OZXSUGGESA-N

# Indication:
For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.

# KEGG_Compound_ID:
C08080

# KEGG_Drug_ID:
D00888

# LIMS_Drug_ID:
251

# Mechanism_Of_Action:
Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.

# Melting_Point:
126.3 Â°C

# Molecular_Weight_Avg:
532.462

# Molecular_Weight_Mono:
531.180395297

# Organisms_Affected:
Fungi

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ter1436.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164768834

# Pharmacology:
Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.

# Predicted_LogP_Hydrophobicity:
4.58

# Predicted_LogS:
-4.7

# Predicted_Water_Solubility:
1.16e-02 g/l

# Primary_Accession_No:
DB00251

# Protein_Binding:
94.9%

# PubChem_Compound_ID:
441383

# PubChem_Substance_ID:
46505257

# RxList_Link:
http://www.rxlist.com/cgi/generic/tercon.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00659

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Triaconazole

# Synthesis_Reference:
Not Available

# Toxicity:
The oral LD<sub>50</sub> values were found to be 1741 and 849 mg/kg for the male and female in rat.

# Update_Date:
2013-02-08 16:19:12 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Terconazole

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
1951574	Vanden Bossche H, Marichal P: Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
2677363	Cauwenbergh G, Vanden Bossche H: Terconazole. Pharmacology of a new antimycotic agent. J Reprod Med. 1989 Aug;34(8 Suppl):588-92.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X13296

# Drug_Target_1_GenBank_ID_Protein:
578119

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ERG11

# Drug_Target_1_Gene_Sequence:
>1587 bp
ATGGCTATTGTTGAAACTGTCATTGATGGCATTAATTATTTTTTGTCCCTTAGTGTTACA
CAACAGATCAGTATATTATTAGGGGTTCCATTTGTTTACAACTTAGTATGGCAATATTTA
TATTCATTAAGAAAAGATAGAGCTCCATTAGTGTTTTATTGGATTCCTTGGTTTGGTTCT
GCAGCTTCATATGGTCAACAACCTTATGAATTTTTCGAATCATGTCGTCAAAAGTATGGT
GATGTATTTTCATTTATGTTATTAGGGAAAATTATGACGGTTTATTTAGGTCCAAAAGGT
CATGAATTTGTTTTTAATGCTAAATTATCTGATGTTTCTGCTGAAGATGCTTATAAACAT
TTAACTACTCCAGTTTTCGGTAAAGGGGTTATTTATGATTGTCCAAATTCCAGATTAATG
GAACAAAAAAAATTTGCTAAATTTGCTTTGACTACTGATTCATTTAAAAGATATGTTCCT
AAGATTAGAGAAGAAATTTTGAATTATTTTGTTACTGATGAAAGTTTCAAATTGAAAGAA
AAAACTCATGGGGTTGCCAATGTTATGAAAACTCAACCAGAAATTACTATTTTCACTGCT
TCAAGATCTTTATTTGGTGATGAAATGAGAAGAATTTTTGACCGTTCATTTGCTCAACTA
TATTCTGATTTAGATAAAGGTTTTACCCCTATTAATTTTGTTTTCCCTAATTTACCTTTA
CCTCATTATTGGAGACGTGATGCTGCTCAAAAGAAAATCTCTGCTACTTATATGAAAGAA
ATTAAACTGAGAAGAGAACGTGGTGATATTGATCCAAATCGTGATTTAATTGATTCCTTA
TTGATTCATTCAACTTATAAAGATGGTGTGAAAATGACTGATCAAGAAATTGCTAATCTT
TTAATTGGTATTCTTATGGGTGGTCAACATACTTCTGCTTCTACTTCTGCTTGGTTCTTG
TTACATTTAGGTGAAAAACCTCATTTACAAGATGTTATTTATCAAGAAGTTGTTGAATTA
TTGAAAGAAAAAGGTGGTGATTTGAATGATTTGACTTATGAAGATTTACAAAAATTACCA
TCAGTCAATAACACTATTAAGGAAACTCTCAGAATGCATATGCCATTACATTCTATTTTT
AGAAAAGTTACTAACCCATTAAGAATCCCTGAAACCAATTATATTGTTCCAAAAGGTCAT
TATGTTTTAGTTTCTCCAGGTTATGCTCATACTAGTGAAAGATATTTTGATAACCCTGAA
GATTTTGATCCAACTAGATGGGATACTGCTGCTGCCAAAGCTAATTCTGTTTCATTTAAC
TCTTCTGATGAAGTTGATTATGGGTTTGGGAAAGTTTCTAAAGGGGTTTCTTCACCTTAT
TTACCATTTGGTGGTGGTAGACATAGATGTATTGGGGAACAATTTGCTTATGTTCAATTA
GGAACCATTTTAACTACTTTTGTTTATAATTTAAGATGGACTATTGATGGTTATAAAGTG
CCTGACCCTGATTATAGTTCAATGGTGGTTTTACCTACTGAACCAGCAGAAATCATTTGG
GAAAAAAGAGAAACTTGTATGTTTTAA

# Drug_Target_1_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_1_General_References:
2644625	Lai MH, Kirsch DR: Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res. 1989 Jan 25;17(2):804.
7819160	Boscott PE, Grant GH: Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam. J Mol Graph. 1994 Sep;12(3):185-92, 195.
9210671	White TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother. 1997 Jul;41(7):1488-94.
9228762	Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H: Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett. 1997 Jun 15;151(2):263-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
260

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
60676

# Drug_Target_1_Name:
Cytochrome P450 51

# Drug_Target_1_Number_of_Residues:
528

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_1_Protein_Sequence:
>Cytochrome P450 51
MAIVETVIDGINYFLSLSVTQQISILLGVPFVYNLVWQYLYSLRKDRAPLVFYWIPWFGS
AASYGQQPYEFFESCRQKYGDVFSFMLLGKIMTVYLGPKGHEFVFNAKLSDVSAEDAYKH
LTTPVFGKGVIYDCPNSRLMEQKKFAKFALTTDSFKRYVPKIREEILNYFVTDESFKLKE
KTHGVANVMKTQPEITIFTASRSLFGDEMRRIFDRSFAQLYSDLDKGFTPINFVFPNLPL
PHYWRRDAAQKKISATYMKEIKSRRERGDIDPNRDLIDSLLIHSTYKDGVKMTDQEIANL
LIGILMGGQHTSASTSAWFLLHLGEKPHLQDVIYQEVVELLKEKGGDLNDLTYEDLQKLP
SVNNTIKETLRMHMPLHSIFRKVTNPLRIPETNYIVPKGHYVLVSPGYAHTSERYFDNPE
DFDPTRWDTAAAKANSVSFNSSDEVDYGFGKVSKGVSSPYLPFGGGRHRCIGEQFAYVQL
GTILTTFVYNLRWTIDGYKVPDPDYSSMVVLPTEPAEIIWEKRETCMF

# Drug_Target_1_Reaction:
obtusifoliol + 3 O2 + 3 NADPH + 3 H+ = 4alpha-methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol + formate + 3 NADP+ + 4 H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol

# Drug_Target_1_SwissProt_ID:
P10613

# Drug_Target_1_SwissProt_Name:
CP51_CANAL

# Drug_Target_1_Synonyms:
CYPLI
EC 1.14.13.70
Lanosterol 14-alpha demethylase
P450-14DM
P450-LIA1
Sterol 14- alpha demethylase

# Drug_Target_1_Theoretical_pI:
7.19

# Drug_Target_1_Transmembrane_Regions:
15-37; 50-69

#END_DRUGCARD DB00251
